{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:32:07Z","timestamp":1790209927209,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Esophageal squamous cell carcinoma (ESCC) with non-regional cervical lymph node metastasis (CLNM) poses significant therapeutic challenges due to lack of consensus in guidelines and poor outcomes associated with conventional treatment modalities. Recent studies have demonstrated promising efficacy of combined immunotherapy, chemotherapy, and surgery in ESCC; however, the role of this multimodal approach in managing non-regional CLNM\u2014historically considered inoperable\u2014remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 15 patients with thoracic ESCC and non-regional CLNM who underwent neoadjuvant chemoimmunotherapy (nCIT), followed by McKeown esophagectomy with three-field lymphadenectomy between 2020 and 2024. CLNM was confirmed via ultrasound-guided biopsy. Data on pathological response, safety, and survival outcomes were collected and analyzed. Survival analysis was performed using the Kaplan-Meier method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A pathological complete response (pCR) in CLNM was achieved in 93.3% of patients, while the Total pCR (ypT0N0M0) rate (clearance of both primary tumor and metastatic lymph node) was 33.3%. At a median follow-up of 18.0 months, the 1-year disease-free survival (DFS) rate was 91.7%. One patient died during the follow-up period. Postoperative complications occurred in 73.3% of patients, predominantly respiratory events such as atelectasis and pneumonia; only one patient experienced a grade 4 event. Treatment-related adverse events (TRAEs) were mild, with no grade \u22653 TRAEs observed; anemia was the most common TRAEs, occurring in 46.7% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>nCIT induces a high cervical nodal response in ESCC with non-regional CLNM and may redefine surgical eligibility for patients with non-regional metastases. The observed 1-year DFS of 91.7% is promising, though long-term outcomes require further validation through prospective studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1611108","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:35:51Z","timestamp":1758000951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with non-regional cervical lymph node metastasis: a retrospective pilot study"],"prefix":"10.3389","volume":"16","author":[{"given":"Chufeng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longgao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12087","article-title":"Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China","volume":"40","author":"He","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11497","article-title":"Three-field versus two-field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short-term outcomes of a randomized clinical trial","volume":"107","author":"Li","year":"2020","journal-title":"Br J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(91)91008-J","article-title":"Evaluation of neck lymph node dissection for thoracic esophageal carcinoma","volume":"51","author":"Kato","year":"1991","journal-title":"Ann Thorac Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1527625","article-title":"Supraclavicular lymph node metastasis in esophageal carcinoma: a topic of ongoing controversy","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dote.12540","article-title":"Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis Esophagus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese Classification of Esophageal Cancer, 12th Edition: Part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"B8","unstructured":"Version 4.2024, 07\/30\/24 \u00a9 2024 National Comprehensive Cancer Network\u00ae (NCCN\u00ae)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-023-00994-1","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13014-018-1145-4","article-title":"Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis","volume":"13","author":"Xu","year":"2018","journal-title":"Radiat Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.05.014","article-title":"Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement","volume":"51","author":"Chung","year":"2019","journal-title":"Dig Liver Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.21037\/atm-22-577","article-title":"Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis","volume":"10","author":"Yu","year":"2022","journal-title":"Ann Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2024.03.031","article-title":"Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score-matched analysis","volume":"28","author":"Tankel","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.18632\/oncotarget.12200","article-title":"Supraclavicular and\/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery","volume":"8","author":"Cho","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1408458","article-title":"PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data","volume":"15","author":"Yan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052542","article-title":"Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42047-019-0033-z","article-title":"Expression of PD-L1 in primary breast carcinoma and lymph node metastases","volume":"2","author":"Alves","year":"2019","journal-title":"Surg Exp Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230904","article-title":"Lymph node metastasis: An immunological burden","volume":"220","author":"Lund","year":"2023","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07915-6","article-title":"Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype","volume":"26","author":"Glaeser","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004142","article-title":"Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy","volume":"11","author":"Fu","year":"2015","journal-title":"PloS Comput Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.011","article-title":"Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy","volume":"99","author":"Liu","year":"2011","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.012","article-title":"Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence","volume":"42","author":"Watson","year":"2024","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1510145","article-title":"Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels","volume":"15","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0161","article-title":"Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer","volume":"2","author":"Graf","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414884","article-title":"Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:35:53Z","timestamp":1758000953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1611108"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1611108","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1611108"}}